Phase 1 trial of CBT-101 in patients with Met-positive Advanced Non-Small Cell Lung Cancer.
Latest Information Update: 03 Oct 2017
Price :
$35 *
At a glance
- Drugs Vebreltinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 03 Oct 2017 New trial record